The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers
Abstract
The inhibition of hepatic uptake transporters, such as OATP1B1, on the pharmacokinetics of atorvastatin is unknown. Here, we investigate the effect of a model hepatic transporter inhibitor, rifampin, on the kinetics of atorvastatin and its metabolites in humans. The inhibitory effect of a single rifampin dose on atorvastatin kinetics was studied in 11 healthy volunteers in a randomized, crossover study. Each subject received two 40-mg doses of atorvastatin, one on study day 1 and one on study day 8, separated by 1 week. One intravenous 30-min infusion of 600 mg rifampin was administered to each subject on either study day 1 or study day 8. Plasma concentrations of atorvastatin and metabolites were above the limits of quantitation for up to 24 h after dosing. Rifampin significantly increased the total area under the plasma concentration-time curve (AUC) of atorvastatin acid by 6.8+/-2.4-fold and that of 2-hydroxy-atorvastatin acid and 4-hydroxy-atorvastatin acid by 6.8+/-2.5- and 3.9+/-2.4-fold, respectively. The AUC values of the lactone forms of atorvastatin, 2-hydroxy-atorvastatin and 4-hydroxy-atorvastatin, were also significantly increased, but to a lower extent. An intravenous dose of rifampin substantially increased the plasma concentrations of atorvastatin and its acid and lactone metabolites. The data confirm that OATP1B transporters represent the major hepatic uptake systems for atorvastatin and its active metabolites. Inhibition of hepatic uptake may have consequences for efficacy and toxicity of drugs like atorvastatin that are mainly eliminated by the hepatobiliary system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Noncompartmental Determination of the Steady‐State Volume of Distribution
Benet, L. Z., & Galeazzi, R. L. (1979) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600680845 · Cited by 735
Self-citationA Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641
Clinical Pharmacokinetics of Atorvastatin
Lennern??s, H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00005 · Cited by 623
König, J., Cui, Y., Nies, A. T., & Keppler, D. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.1.g156 · Cited by 620
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 576
Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1
Abe, T., Kakyo, M., Tokui, T., Nakagomi, R., Nishio, T., Nakai, D., Nomura, H., Unno, M., Suzuki, M., Naitoh, T., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17159 · Cited by 543
Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting Polypeptide
König, J., Cui, Y., Nies, A. T., & Keppler, D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001448200 · Cited by 522
Hepatic Uptake of Bilirubin and Its Conjugates by the Human Organic Anion Transporter SLC21A6
Cui, Y., König, J., Leier, I., Buchholz, U., & Keppler, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004968200 · Cited by 515
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
Nawrocki, J. W., Weiss, S. R., Davidson, M. H., Sprecher, D. L., Schwartz, S. L., Lupien, P.-J., Jones, P. H., Haber, H. E., & Black, D. M. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.678 · Cited by 484
Niemi, M., Schaeffeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., Backman, J. T., Kerb, R., Schwab, M., Neuvonen, P. J., et al. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114750.08559.32 · Cited by 418
Shitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407
Clinical Pharmacokinetics of Rifampicin
Acocella, G. (1978) · Clinical Pharmacokinetics · doi:10.2165/00003088-197803020-00002 · Cited by 405
Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M., & Chiba, K. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000170913.73780.5f · Cited by 379
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver
Vavricka, S. R., Van Montfoort, J., Ha, H. R., Meier, P. J., & Fattinger, K. (2002) · Hepatology · doi:10.1053/jhep.2002.34133 · Cited by 373
NIEMI, M., BACKMAN, J., KAJOSAARI, L., LEATHART, J., NEUVONEN, M., DALY, A., EICHELBAUM, M., KIVISTO, K., & NEUVONEN, P. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.018 · Cited by 360
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
Prueksaritanont, T., Subramanian, R., Fang, X., Ma, B., Qiu, Y., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.505 · Cited by 344
Shitara, Y., Itoh, T., Sato, H., Li, A. P., & Sugiyama, Y. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041921 · Cited by 340
Tirona, R. G., Leake, B. F., Wolkoff, A. W., & Kim, R. B. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.043026 · Cited by 324
Effect of itraconazole on the pharmacokinetics of atorvastatin*
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90023-6 · Cited by 300
Molecular Characterization and Inhibition of Amanitin Uptake into Human Hepatocytes
Letschert, K., Faulstich, H., Keller, D., & Keppler, D. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj141 · Cited by 298
The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters
Fromm, M. F., Kauffmann, H.-M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., Eichelbaum, M., Siegmund, W., & Schrenk, D. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64794-3 · Cited by 277
Schuetz, E. G., Schinkel, A. H., Relling, M. V., & Schuetz, J. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4001 · Cited by 266
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
LILJA, J., KIVISTO, K., & NEUVONEN, P. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)90048-6 · Cited by 241
Jacobsen, W., Kuhn, B., Soldner, A., Kirchner, G., Sewing, K.-F., Kollman, P. A., Benet, L. Z., & Christians, U. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15086-6 · Cited by 236
Self-citationChen, C., Mireles, R. J., Campbell, S. D., Lin, J., Mills, J. B., Xu, J. J., & Smolarek, T. A. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002477 · Cited by 209
The Organic Anion Transporter (OATP) Family
Mikkaichi, T., Suzuki, T., Tanemoto, M., Ito, S., & Abe, T. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.171 · Cited by 191
Wu, X., Whitfield, L. R., & Stewart, B. H. (2000) · Pharmaceutical Research · doi:10.1023/a:1007525616017 · Cited by 189
Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin
Kajosaari, L. I., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_157.x · Cited by 172
Backman, J. T., Luurila, H., Neuvonen, M., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.04.007 · Cited by 156
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination
Smith, N. F., Figg, W. D., & Sparreboom, A. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.429 · Cited by 148
Iwai, M., Suzuki, H., Ieiri, I., Otsubo, K., & Sugiyama, Y. (2004) · Pharmacogenetics · doi:10.1097/00008571-200411000-00006 · Cited by 147
Multispecific amphipathic substrate transport by an organic anion transporter of human liver
Bossuyt, X., Müller, M., & Meier, P. J. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80246-7 · Cited by 140
Lau, Y. Y., Okochi, H., Huang, Y. L., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093088 · Cited by 140
Self-citationJemal, M., Ouyang, Z., Chen, B., & Teitz, D. S. (1999) · Rapid Communications in Mass Spectrometry · Cited by 139
Niemi, M., Kivistö, K. T., Hofmann, U., Schwab, M. G., Eichelbaum, M. F., & Fromm, M. F. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02354.x · Cited by 135
Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations
Siedlik, P. H., Olson, S. C., Yang, B., & Stern, R. H. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/009127009903900510 · Cited by 110
Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin
Hochman, J. H., Pudvah, N. T., Qiu, J., Yamazaki, M., Tang, C., Lin, J. H., & Prueksaritanont, T. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000041466.84653.8c · Cited by 109
Lau, Y. Y., Okochi, H., Huang, Y., & Benet, L. Z. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.009076 · Cited by 109
Self-citationYamazaki, M., LI, B., Louie, S. W., Pudvah, N. T., Stocco, R., Wong, W., Abramovitz, M., Demartis, A., Laufer, R., Hochman, J. H., et al. (2005) · Xenobiotica · doi:10.1080/00498250500136676 · Cited by 95
Introduction: Transport across the hepatocyte canalicular membrane
KEPPLER, D. O. R., & Arias, I. M. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.1.9034161 · Cited by 94
Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide
Bidstrup, T. B., Stilling, N. M., Damkier, P., Scharling, B., Thomsen, M. S., & Brøsen, K. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0746-z · Cited by 84
Hermann, M., Åsberg, A., Christensen, H., Holdaas, H., Hartmann, A., & Reubsaet, L. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.07.008 · Cited by 69
Hepatobiliary transport of bile acids and organic anions.
Takikawa, H. (2002) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s005340200055 · Cited by 54
Cui, Y., & Walter, B. (2003) · Journal of Gastroenterology · doi:10.1007/s005350300007 · Cited by 20
Cited by
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery
Smith, D. A., Di, L., & Kerns, E. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3287 · Cited by 898
Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation
Klaassen, C. D., & Aleksunes, L. M. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002014 · Cited by 807
Roth, M., Obaidat, A., & Hagenbuch, B. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01724.x · Cited by 767
Pharmacokinetics and dosage adjustment in patients with renal dysfunction
Verbeeck, R. K., & Musuamba, F. T. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0678-8 · Cited by 717
Metadata
- Authors
- Lau, Y. Y., Huang, Y., Frassetto, L., & Benet, L. Z.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2006-12-27
- Volume
- 81
- Issue
- 2
- Pages
- 194-204
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2131138924
- Cited by
- 327
- References
- 48
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.